Stock SUVEN SUVEN LIFE SCIENCES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Suven Life Sciences Limited

Equities

SUVEN

INE495B01038

Market Closed - Bombay S.E.
Other stock markets
 06:00:48 2024-04-30 am EDT 		5-day change 1st Jan Change
110.3 INR -1.24% Intraday chart for Suven Life Sciences Limited +3.72% +36.75%
Apr. 15 Suven Life Sciences to Present Phase-2 Positive Results on Samelisant (SUVN-G3031) at American Academy of Neurology 2024 Annual Meeting, Denver, USA CI
Feb. 06 Suven Life Sciences Announces Randomization of First Patient in Phase-2 POC Clinical Trial of Ropanicant (SUVN-911) for the Treatment of Moderate to Severe Major Depressive Disorder Study in USA CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Suven Life Sciences : October 30, 2023Suven Life Sciences announces Positive Topline Results from a Phase-2 study evaluating Samelisant
PU
October 24, 2023Suven Life Sciences Announces Scientific Presentation at CTAD-2023: Study Design of Global Phase-3
PU
Suven Life Sciences : July 17, 2023Suven Life Announces Clinical and Preclinical data Poster Presentations at AAIC 2023, Amsterdam.
PU
Suven Life Sciences : Form MGT-7 FY 2022-23
PU
Suven Life Sciences : Annual Report FY 2022-23 (Book)
PU
Suven Life Sciences : Annual Report 2022-2023
PU
Suven Life Sciences announces two poster presentations including patient baseline characteristics and demographics from the phase-2 Proof of Concept study on samelisant at the SLEEP-2023 annual meeting
AQ
Suven Life Sciences : June 03, 2023Suven announces two poster presentations from the phase-2 (PoC) study on samelisant (SUVN-G3031)
PU
Suven Life Sciences : June 01, 2023Suven completed enrollment of patients to the phase-2(PoC) clinical study of SUVN-G3031 in US,CANADA
PU
Suven Life Sciences : Schedule of Conference Call for Investors on May 26, 2023
PU
Suven Life Sciences : Outcome of the Board Meeting
PU
Suven Life Sciences : Schedule of Conference Call for Investors on February 7, 2023
PU
Suven Life Sciences : Conference Call Transcript on December 26, 2022
PU
Suven Life Sciences : Schedule of Conference Call for Investors on December 26, 2022
PU
Suven Life Sciences : Disclosure under Regulation 30
PU
Suven Life Sciences Presenting Study Design and Initiation of Phase-3 Global Clinical Trial of 'Masupirdine (SUVN-502)
AQ
Suven Life Sciences : November 29, 2022Suven Presenting Study Design,Initiation of Phase-3 Global Clinical Trial of Masupirdine (SUVN-502)
PU
Suven Life Sciences : Newspaper Advertisements
PU
Suven Life Sciences Limited Announces Randomization of First Patient in Phase-3 Global Clinical Trial of Masupirdine for the Treatment of Agitation in Patients with Dementia of the Alzheimer's Type
AQ
Suven Life Sciences : Rights Issue
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SUVEN Stock
  4. News Suven Life Sciences Limited
  5. Press Releases